NeoGenomics Inc. (NASDAQ: NEO)’s stock price has dropped by 0.00 in relation to previous closing price of 13.72. Nevertheless, the company has seen a loss of -2.07% in its stock price over the last five trading days. Seeking Alpha reported 2023-08-08 that NeoGenomics, Inc (NASDAQ:NEO ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Kendra Sweeney – Vice President, Investor Relations Chris Smith – Chief Executive Officer Jeff Sherman – Chief Financial Officer Vishal Sikri – President, Advanced Diagnostics Warren Stone – President, Clinical Services Melody Harris – President, Enterprise Operations Conference Call Participants Dan Brennan – TD Cowen Alex Nowak – Craig-Hallum Capital Group David Delahunt – Goldman Sachs Mark Massaro – BTIG Tejas Savant – Morgan Stanley Derik De Bruin – Bank of America Mike Matson – Needham & Company Mason Carrico – Stephens Andrew Cooper – Raymond James Operator Welcome to the NeoGenomics Second Quarter 2023 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode.
Is It Worth Investing in NeoGenomics Inc. (NASDAQ: NEO) Right Now?
, and the 36-month beta value for NEO is at 1.09. Analysts have varying views on the stock, with 10 analysts rating it as a “buy,” 0 rating it as “overweight,” 3 as “hold,” and 0 as “sell.”
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
The average price suggested by analysts for NEO is $21.18, which is $7.46 above the current market price. The public float for NEO is 125.50M, and currently, shorts hold a 4.36% of that float. The average trading volume for NEO on September 15, 2023 was 804.65K shares.
NEO’s Market Performance
The stock of NeoGenomics Inc. (NEO) has seen a -2.07% decrease in the past week, with a 1.48% rise in the past month, and a -17.50% fall in the past quarter. The volatility ratio for the week is 4.33%, and the volatility levels for the past 30 days are at 4.12% for NEO. The simple moving average for the past 20 days is -2.50% for NEO’s stock, with a -7.17% simple moving average for the past 200 days.
Analysts’ Opinion of NEO
Many brokerage firms have already submitted their reports for NEO stocks, with Stephens repeating the rating for NEO by listing it as a “Overweight.” The predicted price for NEO in the upcoming period, according to Stephens is $18 based on the research report published on August 21, 2023 of the current year 2023.
NEO Trading at -10.82% from the 50-Day Moving Average
After a stumble in the market that brought NEO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.20% of loss for the given period.
Volatility was left at 4.12%, however, over the last 30 days, the volatility rate increased by 4.33%, as shares sank -0.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.94% lower at present.
During the last 5 trading sessions, NEO fell by -2.07%, which changed the moving average for the period of 200-days by +33.72% in comparison to the 20-day moving average, which settled at $14.07. In addition, NeoGenomics Inc. saw 48.48% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for NEO
Current profitability levels for the company are sitting at:
- -29.55 for the present operating margin
- +33.99 for the gross margin
The net margin for NeoGenomics Inc. stands at -28.30. The total capital return value is set at -9.05, while invested capital returns managed to touch -8.70. Equity return is now at value -11.60, with -6.60 for asset returns.
Based on NeoGenomics Inc. (NEO), the company’s capital structure generated 61.21 points at debt to equity in total, while total debt to capital is 37.97. Total debt to assets is 35.11, with long-term debt to equity ratio resting at 60.55. Finally, the long-term debt to capital ratio is 37.56.
When we switch over and look at the enterprise to sales, we see a ratio of 3.49, with the company’s debt to enterprise value settled at 0.46. The receivables turnover for the company is 4.30 and the total asset turnover is 0.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.73.
Conclusion
In conclusion, NeoGenomics Inc. (NEO) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
